Key Drivers
- High operating margins
- Negative equity
- Strong free cash
AIAI Summary
Treat IRWD as a leveraged, cash-generating specialty pharma—LINZESS-driven FCF and high incremental margins mean the company can self-fund near-term apraglutide Phase 3 and deserves valuation based on sustained commercial execution rather than a single binary trial readout. Key actionable monitorables: consecutive quarters of stable/improving LINZESS demand and visible deleveraging (debt paydown or equity-neutral refinancing) are required to materially de-risk the balance sheet; another quarter of margin erosion or a need for dilutive capital would sharply worsen the thesis.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High operating margins
- •Negative equity
- •Strong free cash
IRWD delivers strong FY profitability and free cash flow but faces a material solvency risk from negative equity and high debt alongside weakening quarterly performance.
Price Behavior
Key Price Behavior Insights:
- •Price above average
- •Low downside risk
- •Resistance headwind
IRWD traded slightly lower over the last month (≈−2%) but remains above its last-month 21-day average, suggesting limited near-term downside with defined support near $3.04 and resistance around $3.65–$3.70 (stronger barrier at $4.78).
Modest ~2% decline over the last month with no sharp sell-off
Sentiment & News
Key News Insights:
- •Soft Linzess sales
- •Insider large sale
- •Pricing & partnerships
Ironwood shares fell ~14% on perceived soft Q4 Linzess sales despite steady prescriptions, improved net pricing, new partnerships and a large insider sale, leaving near-term weakness but potential 2026 upside.
Expect continued short-term volatility driven by sentiment and insider activity, while fundamentals and partnership catalysts could enable a 2026 recovery
Similar Companies in Healthcare
Other companies in the same sector with AI ratings